451 related articles for article (PubMed ID: 17956937)
1. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach.
Tajiri M; Ohyama C; Wada Y
Glycobiology; 2008 Jan; 18(1):2-8. PubMed ID: 17956937
[TBL] [Abstract][Full Text] [Related]
2. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins.
Peracaula R; Tabarés G; Royle L; Harvey DJ; Dwek RA; Rudd PM; de Llorens R
Glycobiology; 2003 Jun; 13(6):457-70. PubMed ID: 12626390
[TBL] [Abstract][Full Text] [Related]
3. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.
Tabarés G; Radcliffe CM; Barrabés S; Ramírez M; Aleixandre RN; Hoesel W; Dwek RA; Rudd PM; Peracaula R; de Llorens R
Glycobiology; 2006 Feb; 16(2):132-45. PubMed ID: 16177264
[TBL] [Abstract][Full Text] [Related]
4. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy.
Ohyama C; Hosono M; Nitta K; Oh-eda M; Yoshikawa K; Habuchi T; Arai Y; Fukuda M
Glycobiology; 2004 Aug; 14(8):671-9. PubMed ID: 15044396
[TBL] [Abstract][Full Text] [Related]
5. Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin.
Lilja H
Urol Clin North Am; 1993 Nov; 20(4):681-6. PubMed ID: 7505976
[TBL] [Abstract][Full Text] [Related]
6. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry.
Peter J; Unverzagt C; Krogh TN; Vorm O; Hoesel W
Cancer Res; 2001 Feb; 61(3):957-62. PubMed ID: 11221890
[TBL] [Abstract][Full Text] [Related]
7. [Molecular forms of prostate-specific antigen and their clinical significance].
Hilz H
Urologe A; 1995 Jul; 34(4):275-82. PubMed ID: 7545841
[TBL] [Abstract][Full Text] [Related]
8. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography.
Wu P; Stenman UH; Pakkala M; Närvänen A; Leinonen J
Prostate; 2004 Mar; 58(4):345-53. PubMed ID: 14968435
[TBL] [Abstract][Full Text] [Related]
9. Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid.
Mattsson JM; Valmu L; Laakkonen P; Stenman UH; Koistinen H
Prostate; 2008 Jun; 68(9):945-54. PubMed ID: 18386289
[TBL] [Abstract][Full Text] [Related]
10. Strategy for sensitive and specific detection of molecular forms of PSA based on 2DE and kinetic analysis: a step towards diagnosis of prostate cancer.
Kumar V; Hassan MI; Singh AK; Dey S; Singh TP; Yadav S
Clin Chim Acta; 2009 May; 403(1-2):17-22. PubMed ID: 19118539
[TBL] [Abstract][Full Text] [Related]
11. Glycan characterization of PSA 2-DE subforms from serum and seminal plasma.
Sarrats A; Saldova R; Comet J; O'Donoghue N; de Llorens R; Rudd PM; Peracaula R
OMICS; 2010 Aug; 14(4):465-74. PubMed ID: 20726802
[TBL] [Abstract][Full Text] [Related]
12. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum.
Mikolajczyk SD; Grauer LS; Millar LS; Hill TM; Kumar A; Rittenhouse HG; Wolfert RL; Saedi MS
Urology; 1997 Nov; 50(5):710-4. PubMed ID: 9372880
[TBL] [Abstract][Full Text] [Related]
13. Characterization of intracellular prostate-specific antigen from laser capture microdissected benign and malignant prostatic epithelium.
Ornstein DK; Englert C; Gillespie JW; Paweletz CP; Linehan WM; Emmert-Buck MR; Petricoin EF
Clin Cancer Res; 2000 Feb; 6(2):353-6. PubMed ID: 10690510
[TBL] [Abstract][Full Text] [Related]
14. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia.
Saldova R; Fan Y; Fitzpatrick JM; Watson RW; Rudd PM
Glycobiology; 2011 Feb; 21(2):195-205. PubMed ID: 20861084
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of human prostate-specific antigen in a sandwich antibody complex.
Stura EA; Muller BH; Bossus M; Michel S; Jolivet-Reynaud C; Ducancel F
J Mol Biol; 2011 Dec; 414(4):530-44. PubMed ID: 22037582
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Mikolajczyk SD; Rittenhouse HG
Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
[TBL] [Abstract][Full Text] [Related]
17. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
Tsuchiya N; Ohyama C; Habuchi T
Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
[TBL] [Abstract][Full Text] [Related]
18. [Enzyme-linked immunosorbent assay for serum prostate specific antigen (PSA) using monoclonal antibodies].
Setoguchi C; Matsumoto K; Samori T; Kimura E; Harukaze S
Rinsho Byori; 1998 Jan; 46(1):79-82. PubMed ID: 9492543
[TBL] [Abstract][Full Text] [Related]
19. Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients.
Holmes EH; Greene TG; Tino WT; Boynton AL; Aldape HC; Misrock SL; Murphy GP
Prostate Suppl; 1996; 7():25-9. PubMed ID: 8950359
[TBL] [Abstract][Full Text] [Related]
20. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
